Recently, the Hurun Research Institute released its inaugural Hurun Global Cheetah Index 2023, listing 747 high‑growth companies from 198 cities across 34 countries that are most likely to reach unicorn status (a valuation of US$1 billion) within five years. Cygnus Bio earned a place on the list thanks to its unique technological innovation in gene sequencing and strong growth potential.
For the ranking, the Hurun Research Institute drew on data provided by top investment institutions and cross‑checked information with professional investment databases, industry experts, media sources, and co‑founders of the cheetah companies. Each company on the list underwent rigorous screening and meticulous data verification. The valuation cut‑off date for this index was December 31, 2022. Listed cheetah companies typically have current valuations between US$300 million and US$500 million. Among them, 66% sell software and services, primarily in enterprise services and fintech, followed by medical technology, biotechnology, and software services; the remaining 34% sell physical products, mainly in biotechnology, health technology, semiconductors, and robotics.
Cygnus Bio's inclusion in the Hurun Global Cheetah Index 2023 is attributable to its distinctive technological innovation and market development advantages. As a high‑throughput gene sequencer manufacturer with original foundational sequencing technologies and full proprietary intellectual property rights, the company possesses strong independent R&D capabilities. It is able to continuously roll out innovative products and services that meet market demands while expanding its market presence at lower cost and higher efficiency, thus achieving sustainable development.
As a representative company holding patented technologies for sequencing systems, Cygnus Bio has always taken innovation as its driving force. It now owns core foundational patented sequencing technologies such as one‑step fluorogenic chemistry and triple error‑correcting code (ECC). The company's first sequencing system, the GS100, has already been launched. Equipped with dual ECC & BitSeq modes, the system features a compact design, simple operation, flexible throughput, high accuracy, and suitability for multiple scenarios.
Looking ahead, Cygnus Bio will continue to be driven by innovation and guided by customer needs, constantly optimizing its products and services. While refining its benchtop product series, the company plans to launch new gene sequencer product lines designed to meet the needs of centralized clinical testing services and to offer more intelligent operation. It aims to provide simpler, more accurate, and more efficient gene sequencing tools and solutions for life sciences research – including biology, medical diagnostics, drug development, animal and plant breeding, customs inspection, disease control, forensic science, and evolutionary studies – delivering an even better sequencing experience to its customers.
